In reply to 'Location of Xpert® MTB/RIF in centralised laboratories in South Africa undermines potential impact' [Correspondence]
Int J Tuberc Lung Dis
.
2012 May 1;16(5):702.
doi: 10.5588/ijtld.12.0131-2.
Authors
A Trébucq
1
,
A D Harries
1
Affiliation
1
Institute of the International Union Against Tuberculosis and Lung Disease, Paris, France.
PMID:
29070250
DOI:
10.5588/ijtld.12.0131-2
No abstract available